Company intelligence / Profile preview

Hangzhou Heze Kunyuan Pharmaceutical

Hangzhou, Zhejiang, Chinahezepharm.com ↗

Ownership: Private
Development stage: Commercial

Overview

Hangzhou Heze Kunyuan Pharmaceutical develops and manufactures generic and innovative drug formulations. It has achieved IND approvals for several programs and holds Chinese marketing authorization for desmopressin oral solution since April 2023. The company also develops advanced soft capsule formulations to improve bioavailability of drugs like abiraterone acetate.

Therapeutic areas: PulmonologyOncologyEndocrinologyNeurologyNephrology
Modalities: Small moleculeCombination small molecule drugs
Industry: Biotech

Partnerships

Baker Norton (Zhejiang) Pharmaceutical Co., Ltd. – technology/license transfer for Preba/prebelin oral solution

Beyond the preview

Go deeper on Hangzhou Heze Kunyuan Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Heze Kunyuan Pharmaceutical.

Explore the full profile